Related Experiment Videos
Nuclear gene targeting using negatively charged liposomes.
C Welz1, W Neuhuber, H Schreier
1Department of Pharmaceutics and Biopharmacy, Philipps University, Ketzerback 63, Marburg, Germany.
International Journal of Pharmaceutics
|March 4, 2000
Summary
Chimeric oligonucleotides show promise for correcting genetic diseases. A novel AVE-3 liposomal formulation enhanced nuclear delivery of these DNA-analogue molecules.
Area of Science:
- Molecular Biology
- Gene Therapy
- Nanotechnology
Background:
- Oligonucleotides are valuable tools for controlling gene activity via base-pairing.
- Chimeric oligonucleotides offer a new approach for correcting single-base mutations, potentially treating genetic diseases.
Purpose of the Study:
- To investigate the intracellular fate of fluorescently labeled chimeric oligonucleotides.
- To evaluate different liposomal formulations for delivering these molecules.
Main Methods:
- A 68-mer DNA-analogue chimeric oligonucleotide was synthesized and fluorescently labeled.
- Oligonucleotides were complexed with protamine sulfate and encapsulated in three liposomal formulations (AVE-3, neutral, negative).
- Intracellular localization was tracked using fluorescence microscopy.
Main Results:
- The AVE-3 liposomal formulation demonstrated superior properties compared to neutral and negatively charged formulations.
- Nuclear localization of the chimeric oligonucleotides was exclusively observed with the AVE-3 formulation.
- Only negatively charged liposomes interacted with the protamine-complexed oligonucleotides.
Conclusions:
- The AVE-3 liposomal formulation significantly enhances the nuclear delivery of chimeric oligonucleotides.
- This delivery system holds potential for gene correction strategies targeting nuclear DNA.
- Further research into liposome-oligonucleotide interactions is warranted.